Navellier & Associates
ARQT icon

Navellier & Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Navellier & Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$512K Sell
19,373
-323
-2% -$8.45K 0.04% 227
2026
Q2 		$516K Buy
19,696
+5,943
+43% +$138K 0.04% 243
2026
Q1 		$324K Buy
+13,753
New +$351K 0.03% 274

Other funds holding ARQT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Navellier & Associates's ARQT Position: Q3 2026 in Review

Navellier & Associates reduced its Arcutis Biotherapeutics (ARQT) stake by 1.6% in Q3 2026, selling an estimated $8.45K and leaving 19,373 shares worth $512K. The position accounts for 0.04% of the portfolio, ranked #227.

Navellier & Associates first reported a position in ARQT in Q1 2026 and has held it in 3 quarters since. The position peaked at $516K in Q2 2026. 212 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Navellier & Associates held 19,373 shares of Arcutis Biotherapeutics worth $512K as of Q3 2026.
  • Navellier & Associates sold 323 Arcutis Biotherapeutics shares in Q3 2026, an estimated $8.45K.
  • Arcutis Biotherapeutics made up 0.04% of Navellier & Associates's portfolio in Q3 2026, its #227 holding.
  • Navellier & Associates first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Navellier & Associates's Arcutis Biotherapeutics position peaked at $516K in Q2 2026.
  • 212 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Navellier & Associates's 13F filing for Q3 2026, filed 12 Nov 2026.